Massachusetts Financial Services Co. MA Cuts Position in Cytokinetics, Incorporated $CYTK

Key Points

• Massachusetts Financial Services cut its stake by 34.1% in Cytokinetics in Q4, selling 169,471 shares and retaining 327,202 shares (about 0.27% of the company) worth $20.79 million.
• Institutional activity was mixed: Woodline Partners boosted its position 676.1% to 1,647,725 shares (~$90.56M) and Deep Track Capital holds 4.3M shares (~$236.33M), signaling large buyer interest alongside the MFS reduction.
• Insiders sold a total of 140,505 shares (~$8.77M) over the last quarter — including CEO Robert I. Blum and EVP Andrew Callos executing ~7.5k-share sales on April 15 under Rule 10b5‑1 plans — with insiders now owning 2.70% of the stock.

Massachusetts Financial Services Co. MA lessened its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 34.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 327,202 shares of the biopharmaceutical company's stock after selling 169,471 shares during the quarter. Massachusetts Financial Services Co. MA owned about 0.27% of Cytokinetics worth $20,790,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in CYTK. Woodline Partners LP grew its holdings in Cytokinetics by 676.1% during the 3rd quarter. Woodline Partners LP now owns 1,647,725 shares of the biopharmaceutical company's stock valued at $90,559,000 after buying an additional 1,435,422 shares in the last quarter. Deep Track Capital LP grew its holdings in Cytokinetics by 17.8% during the 3rd quarter. Deep Track Capital LP now owns 4,300,000 shares of the biopharmaceutical company's stock valued at $236,328,000 after buying an additional 650,000 shares in the last quarter. Foresite Capital Management IV LLC purchased a new position in Cytokinetics during the 3rd quarter valued at approximately $25,188,000. Rosalind Advisors Inc. purchased a new position in Cytokinetics during the 2nd quarter valued at approximately $13,216,000. Finally, Vestal Point Capital LP grew its holdings in Cytokinetics by 14.8% during the 2nd quarter. Vestal Point Capital LP now owns 2,975,000 shares of the biopharmaceutical company's stock valued at $98,294,000 after buying an additional 384,469 shares in the last quarter.

Insiders Place Their Bets

In related news, CEO Robert I. Blum sold 7,500 shares of the firm's stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $65.38, for a total transaction of $490,350.00. Following the completion of the sale, the chief executive officer directly owned 415,330 shares of the company's stock, valued at approximately $27,154,275.40. This trade represents a 1.77% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Andrew Callos sold 7,449 shares of the firm's stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $66.02, for a total value of $491,782.98. Following the sale, the executive vice president directly owned 58,555 shares of the company's stock, valued at $3,865,801.10. This represents a 11.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 140,505 shares of company stock valued at $8,766,875 over the last quarter. 2.70% of the stock is currently owned by insiders.

Cytokinetics Price Performance

NASDAQ:CYTK opened at $65.37 on Thursday. The firm has a market capitalization of $8.05 billion, a price-to-earnings ratio of -10.01 and a beta of 0.47. Cytokinetics, Incorporated has a 1 year low of $29.31 and a 1 year high of $70.98. The business has a 50 day simple moving average of $64.01 and a 200-day simple moving average of $63.04.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last posted its quarterly earnings data on Tuesday, February 24th. The biopharmaceutical company reported ($1.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.48) by ($0.02). The firm had revenue of $17.76 million during the quarter, compared to analyst estimates of $8.02 million. Cytokinetics's revenue was up 4.9% on a year-over-year basis. During the same period last year, the firm earned ($1.26) earnings per share. As a group, analysts expect that Cytokinetics, Incorporated will post -5.24 earnings per share for the current fiscal year.

Analyst Ratings Changes

CYTK has been the subject of several research analyst reports. Jefferies Financial Group restated a "buy" rating and set a $90.00 price target on shares of Cytokinetics in a report on Friday, January 9th. Mizuho raised their price target on Cytokinetics from $84.00 to $100.00 and gave the company an "outperform" rating in a report on Wednesday, March 18th. Citigroup reaffirmed a "market outperform" rating on shares of Cytokinetics in a research note on Monday, December 22nd. Citizens Jmp raised their price objective on Cytokinetics from $88.00 to $96.00 and gave the company a "market outperform" rating in a research note on Wednesday, February 25th. Finally, Barclays raised their price objective on Cytokinetics from $87.00 to $95.00 and gave the company an "overweight" rating in a research note on Monday, April 6th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $90.55.

Cytokinetics Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company's most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.